Logo
Login
$ERAS
$15.22 +$0.23 (1.53%) Close

Company Executives

$ERAS Management Team

Mr. Ebun Garner

General Counsel

Corporate Secretary

Age 53
Compensation $2.022M USD
Sex Male

Dr. Shannon Morris

Chief Medical Officer

Age 55
Compensation $1.588M USD
Sex Female

Dr. Jonathan Lim

Chairman of the Board

Chief Executive Officer

Co-Founder

Age 53
Compensation $3.894M USD
Sex Male

Dr. David Chacko

Chief Financial Officer and Chief Business Officer

Age 42
Compensation $1.885M USD
Sex Male

Dr. Michael Varney

Director

Chair of Research and Development and Scientific Advisory Board member

Age 66
Compensation $175.5K USD
Sex Male

Board of Directors

From the proxy statement filed Apr 28, 2026
Directors
8
serving now
Independent
6 of 8
stated in the proxy
Average tenure
6.6 years
from year joined
CEO also chairs the board
Yes
Jonathan E. Lim
Director Age On board Independent Committees Other public boards 2025 pay Source
Alexander W. Casdin
Not stated 2018
8 years
 Independent None stated None stated $176,908
Julie Hambleton
Not stated 2021
5 years
 Independent None stated None stated $175,408
Michael D. Varney
Not stated 2020
6 years
 Not independent None stated None stated Not stated
Jean I. Liu
Not stated 2022
4 years
 Independent None stated Connect Biopharma Holdings Limited $169,408
Pratik S. Multani
Not stated 2018
8 years
 Independent None stated None stated $166,908
Jonathan E. Lim
Board chair, CEO
 Not stated Not stated Not independent None stated Maze Therapeutics, Inc., Boundless Bio, Inc. Paid as CEO
James A. Bristol
Not stated 2018
8 years
 Independent None stated Ernexa Therapeutics, Inc. Not stated
Valerie Harding-Start
Not stated 2019
7 years
 Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans